Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study.

Abstract

Eighty-four previously untreated patients with metastatic adenocarcinoma of the large intestine received intravenous ftorafur at a dosage of 2.25 g/m2/day for 5 consecutive days. Courses were repeated every three weeks. Regressions were noted in 9 of 84 treated patients (11%). Median survival for all patients was 32 weeks. Responders survived only 5 weeks longer than nonresponders; 36 vs. 31 weeks. Central nervous system toxicity was a limiting factor occurring in one-third of patients. Ftorafur in a daily X5 schedule appears not to make a significant contribution to the management of disseminated colorectal cancer.

• Authors: T Buroker, F Padilla, C Groppe, G Guy, J Quagliana, J McCracken, V K Vaitkevicius, B Hoogstraten, L Heilbrun
• Journal: Cancer (Cancer) Vol. 44 Issue 1 Pg. 48-51 (Jul 1979) ISSN: 0008-543X [Print] United States
• PMID: 378365 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Tegafur
• Fluorouracil

Topics

• Adenocarcinoma (drug therapy)
• Adult
• Aged
• Central Nervous System (drug effects)
• Colonic Neoplasms (drug therapy)
• Drug Evaluation
• Female
• Fluorouracil (analogs & derivatives)
• Humans
• Male
• Middle Aged
• Neoplasm Metastasis
• Rectal Neoplasms (drug therapy)
• Remission, Spontaneous
• Tegafur (adverse effects, pharmacology)
• Time Factors